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ABSTRACT
Acute graft-versus-host disease (GVHD) is still a major complication after allogeneic stem cell transplantation.
It is initiated by infiltrating donor T cells specific against the host antigens. Because T-cell migration is largely
controlled by the expression of chemokines and chemokine receptors, we investigated the relation of acute
GVHD and chemokine receptor expression in peripheral blood in 50 patients after allogeneic stem cell
transplantation. The gene expression of the chemokine receptors CCR1, CCR2, CCR5, and CXCR3 was
monitored by using quantitative real-time polymerase chain reaction. Among the 36 patients diagnosed with
acute GVHD, 10 developed a second episode of acute GVHD. Therefore, gene-expression levels could be
analyzed in 46 occasions of acute GVHD. When all 4 markers were evaluated at the same time, increased
gene-expression levels of at least 1 of the 4 markers were seen in 44 of 46 episodes of acute GVHD. The
median increase of the 4 markers ranged from 3 to 12 in connection with acute GVHD. It is interesting to
note that we saw increasing gene-expression levels a few days before acute GVHD was diagnosed clinically at
17, 15, 22, and 19 occasions for CCR5, CXCR3, CCR1, and CCR2, respectively. The median number of days
before diagnosis ranged from 3 to 5. Although they are not specific for acute GVHD, quantitative monitoring
of the gene expression of chemokine receptors may be a valuable molecular method to monitor and diagnose
acute GVHD.
© 2005 American Society for Blood and Marrow Transplantation
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gNTRODUCTION
Despite improvements in allogeneic stem cell
ransplantation (SCT), acute graft-versus-host disease
GVHD) remains a signiﬁcant problem after trans-
lantation [1,2]. In this process, donor T cells recog-
ize alloantigen on host-derived antigen-presenting
ells and induce local tissue injury and an inﬂamma-
ory response [3,4]. A characteristic feature of all in-
ammatory reactions is the excessive recruitment of
eukocytes to the site of inﬂammation. To exert a
athologic effect, T cells must leave the blood and
nter tissues. The process of leukocyte recruitment to
arget tissue is well orchestrated and involves several
rotein families, including proinﬂammatory cyto-
ines, adhesion molecules, matrix metalloproteinases, o
80nd the large cytokine subfamily of chemotactic cyto-
ines, the chemokines [5,6].
Chemokines are a large family of small proteins
hat are distinguished from other cytokines by being
he only members of the cytokine family that act on
he superfamily of G protein–coupled serpentine re-
eptors. [7] They deliver their activity by interacting
ith cell surface–expressed chemokine receptors. In-
ammatory chemokines are expressed in inﬂamed tis-
ues by inﬁltrated cells, monocytes, macrophages, res-
dent cells, or epithelial, endothelial, or ﬁbroblastic
ells on stimulation by proinﬂammatory cytokines (eg,
nterleukin-1, tumor necrosis factor- or interfer-
n-) or stimuli (eg, lipopolysaccharide) [6]. This
roup of chemokines is specialized for the recruitment
f effector cells, including monocytes, granulocytes,
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Chemokine Receptors and Acute GVHD
Bnd effector T cells. Although chemokines have been
mplicated in the recruitment of inﬂammatory cells in
utoimmune diseases and graft rejection, [8-10] until
ow few studies have shown the involvement of che-
okines in the pathogenesis of GVHD. However,
everal chemokines, such as macrophage inﬂamma-
ory protein (MIP)-1, MIP-2, and Mig, have been
hown to be overexpressed in the GVHD target or-
ans (liver, skin, and spleen) in mice [11]. The selec-
ive recruitment of leukocytes at inﬂammation- and
mmune-response sites has been explained by the spe-
iﬁc expression of chemokine receptors on each type
f leukocyte. Chemokine receptors, such as CCR5
nd CXCR3, have been shown to be involved in acute
ejection after heart transplantation in people [12,13]
nd in mice [14] and to be involved in acute lung
llograft rejection in rats [15]. The involvement of
hemokine receptors in acute GVHD has, to our
nowledge, been shown only in mouse models [11,16].
CCR1, CCR2, CCR5, and CXCR3 are chemo-
ine receptors that have been found to be expressed on
he surface of activated T cells, particularly after in-
erleukin-2 stimulation [17-20]. Because activated T
ells are crucial for the development of acute GVHD,
he recruitment of these effector cells to the target
rgans may have a rather important role in this pro-
ess. Therefore, this study analyzed the expression of
he chemokine receptor genes CCR1, CCR2, CCR5,
nd CXCR3 and tested the correlation of this expres-
ion with the presence or absence of acute GVHD
fter allogeneic SCT.
ATERIALS AND METHODS
atients
Fifty patients who underwent allogeneic SCT
etween August 2000 and September 2001 at the
enter for Allogeneic Stem Cell Transplantation at
arolinska University Hospital in Huddinge were in-
luded in this study. Most of the patients had a hema-
ologic malignancy. Conditioning therapy consisted of
combination of cyclophosphamide 120 mg/kg and
usulfan 16 mg/kg (n  15) or a combination of
ractionated total body irradiation 4  3 Gy and cy-
lophosphamide (n  16) [21]. Nineteen patients re-
eived reduced-intensity conditioning. Eight of these
atients received ﬂudarabine 30 mg/m2 for 6 consec-
tive days, oral busulfan 4 mg/kg/d for 2 days, and
ntithymocyte globulin (ATG) [22]. Five patients re-
eived ﬂudarabine 30 mg/m2 for 5 days and cyclo-
hosphamide 60 mg/kg for 2 days according to Childs
t al. [23]. The remaining 6 patients received condi-
ioning regimens consisting of 200 cGy of total body
rradiation combined with 3 to 6 days of ﬂudarabine
0 mg/m2/d [24]. All patients with matched unrelated
onor transplants and most patients who received re- n
B&MTuced-intensity conditioning were given ATG (Thy-
oglobulin; Sangstat, Fremont, CA) 4 to 8 mg/kg/d
or 3 to 5 days, given from day 5 or day 3 until
ay 1.
Twenty-ﬁve patients were given stem cells from
LA-identical siblings, and 25 were given stem cells
rom an HLA-matched unrelated donor. HLA class I
-A and -B) and HLA class II (-DR) antigens were
etermined with polymerase chain reaction (PCR) by
sing sequence-speciﬁc primer pairs [25]. As an alter-
ative to bone marrow, 33 patients were given periph-
ral blood stem cells from donors treated with gran-
locyte colony-stimulating factor. GVHD prophylaxis
onsisted of a combination of either cyclosporin A and
ethotrexate or cyclosporin A and mycophenolate
ofetil [26]. Acute GVHD was diagnosed according
o clinical and histopathologic criteria [27]. At the ﬁrst
ign of grade I acute GVHD, prednisolone 2 mg/kg/d
as given to adults and 2 to 3 mg/kg/d was given to
hildren for at least 1 week [28]. Some patients with
ersistent or severe GVHD also received 6-methyl-
rednisolone (250-500 mg intravenously), ATG, or
soralen and UV light. Patient characteristics are
ummarized in Table 1.
Details regarding the transplantation and support-
ve care have been published elsewhere [28,29]. The
thics Committee at Karolinska Institutet, Karolinska
niversity Hospital in Huddinge (339/00), approved
his study.
ytomegalovirus Detection and Treatment
Patients were monitored for cytomegalovirus
CMV) infection by using a semiquantitative leuko-
yte-based PCR technique to detect CMV DNA [30]
r by using the nucleic acid sequence-based ampliﬁ-
ation assay to detect human CMV-speciﬁc messenger
NA (mRNA) [31]. Preemptive antiviral therapy was
tarted immediately after 2 positive DNA PCR tests
r 1 positive nucleic acid sequence-based ampliﬁca-
ion test. All patients with CMV infection in this study
ere treated with ganciclovir (5 mg/kg twice daily).
atients who did not respond to treatment were given
oscarnet (60 mg/kg twice daily) or cidofovir (5 mg/
g/wk for 2 weeks). If the PCR test for CMV DNA in
eukocytes became negative after 2 weeks of therapy,
he medication was discontinued; if not, maintenance
herapy was given with ganciclovir 5 mg/kg or foscar-
et 90 mg/kg once a day until a negative PCR was
ound [32].
pecimens
Peripheral blood samples were collected from pa-
ients in general on day 14, 21, and 28 and 6 and 8
eeks after SCT. An extra sample was taken in con-
ection with a diagnosis of acute GVHD. The median
umber of blood samples analyzed for each patient
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2as 7 (range, 4-11). In all, 342 peripheral blood sam-
les were analyzed for the gene expression of CCR5,
XCR3, CCR1, and CCR2.
NA Extraction and Reverse Transcription
Total RNA was isolated from peripheral blood
uffy coats obtained by centrifugation (400 g for 10
inutes) by using the QIAAMP RNA blood Mini-Kit
Qiagen, Hilden, Germany). Six milliliters of red cell
ysis buffer was used for 1 mL of buffy coat. Total
NA was extracted from the cell lysate according to
he manufacturer’s instructions. Complementary DNA
cDNA) was synthesized in a total volume of 50 L
ontaining 30 L of RNA, 1 ﬁrst-strand buffer (sup-
lied with reverse transcriptase [RT]), random hex-
mer oligonucleotide primer (105 g/mL; Pharmacia
iotech, Uppsala, Sweden), deoxynucleoside triphos-
hates (1 mmol/L of each; Pharmacia Biotech), di-
hiothreitol (1 mmol/L; supplied with RT), RNasin
0.5 U/L; Promega, Madison, WI), and Moloney
urine leukemia virus RT (4.8 U/L; Invitrogen,
able 1. Patient Characteristics (n  50)
Variable Data
iagnosis
AML 14
ALL 10
CML 9
Other hematologic malignancies 7
Nonmalignant disorders 3
Solid tumors 7
ecipient age, y median (range) 41 (6-67)
ecipient sex (M/F) 23/27
onor age, y median (range) 38 (4-71)
onor sex (M/F) 26/24
ell source (BM/PBSC) 17/33
onor (Sib/MUD) 25/25
onditioning
TBI  Cy 16
Bu  Cy 15
RIC 19
ATG 32
VHD prophylaxis
MTX  CsA 42
MMF  CsA 8
HVD
0 14
I 21
II 10
III 2
IV 3
ML indicates acute myeloid leukemia; ALL, acute lymphoid leu-
kemia; CML, chronic myeloid leukemia; M, male; F, female;
BM, bone marrow; PBSC, peripheral blood stem cells; Sib,
sibling; MUD, matched unrelated donor; TBI, total body irra-
diation; Bu, busulfan; Cy, cyclophosphamide; RIC, reduced-
intensity conditioning; ATG, antithymocyte globulin; GVHD,
graft-versus-host disease; MTX, methotrexate; CsA, cyclosporin
A; MMF, mycophenolate mofetil.aisley, Scotland) at 37°C for 1.5 hours. The reaction s
82as terminated for 15 minutes at 68°C, and cDNA
as stored at 20°C pending further use.
eal-Time Quantitative RT-PCR
Real-time quantiﬁcation of cDNA was performed
ith an ABI Prism 7000 Sequence Detection System
Applied Biosystems, Foster City, CA). Primers and
robes for CCR5, CXCR3, CCR1, CCR2, and glu-
ose-6-phosphate dehydrogenase (G6PD) were se-
ected by using Primer Express software version 2.0
Applied Biosystems; Table 2). The TaqMan probes
ontain the ﬂuorophores 5=FAM as a reporter and
=TAMRA as a quencher. Each set of TaqMan prim-
rs/probes was designed to target cDNA alone with-
ut contaminating DNA. Primer sets and probes were
ommercially synthesized by CyberGene (Huddinge,
weden).
PCR reactions were performed in duplicate in
6-well optical plates in a total volume of 25 L.
ach reaction contained 2.5 L of cDNA, 12.5 L
f TaqMan Universal Master Mix (containing de-
xynucleoside triphosphates with deoxyuridine tri-
hosphate), MgCl2, DNA polymerase (AmpTaq
old), Passive Reference (ROX) (Applied Biosys-
ems), 300 nmol/L of each TaqMan primer, and 200
mol/L of TaqMan probe. Positive and negative con-
rols were included in all runs. Thermal cycling con-
itions were 2 minutes at 50°C initially and 10 min-
tes at 95°C, as recommended by the manufacturer.
ycle conditions were 40 cycles at 95°C for 15 sec-
nds and at 60°C for 1 minute. The housekeeping
ene G6PD was included as an endogenous normal-
zation control, which was used to conﬁrm successful
NA isolation and RT and the total amount of RNA
n every sample. In this study, no standard curves were
sed for quantiﬁcation. To calculate the relative gene
xpression, we used the comparative Ct method
User Bulletin 2, ABI Prism 7700 SDS, Applied Bio-
ystems). With this method, results were calculated as
he ratio between the gene of interest (CCR5,
XCR3, CCR1, and CCR2) and the endogenous con-
rol in the same sample. The mRNA expression levels
re expressed as the -fold increase of chemokine re-
eptor expression level normalized to G6PD. The
ntra-assay coefﬁcient of variation for this method was
10% for all markers. Throughout this study, a
-fold increase was accepted as a signiﬁcant increase.
n each sample, transcription levels were compared
ith the microbiologic and histologic diagnoses estab-
ished by conventional methods.
ESULTS
atients
Twenty-eight of the 50 patients included in this
tudy are alive. Acute GVHD was diagnosed in 36 of
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Chemokine Receptors and Acute GVHD
Bhe 50 patients during the study period after SCT.
owever, 46 episodes of acute GVHD were seen in
hese patients because in 10 patients the acute GVHD
ecurred. Acute GVHD grade I was diagnosed in 21
atients, grade II in 10, grade III in 2, and grade IV in
. The median time for development of acute GVHD
as 22 days (range, 9-116 days) after SCT. Thirty-one
atients became CMV PCR positive during the study
eriod. The median day for diagnosis of CMV infec-
ion was day 27 (range, day 7 to day 84).
cute GVHD and Chemokine Receptor
ene Expression
Among the 36 patients diagnosed with acute
VHD, 46 occasions of acute GVHD were assessed
or the gene-expression levels of CCR5, CXCR3,
CR1, and CCR2. The increase of gene expression
as calculated as the ratio of mRNA expression levels
t the time of acute GVHD compared with the
RNA levels in samples taken before acute GVHD
as diagnosed. The results for acute GVHD and gene
xpression are summarized in Table 3.
able 2. Primers and TaqMan Probes
Gene
CR1
TaqMan sense 5=-CAC GGA CAA AGT CCC
Taqman antisense 5=-TGT GGT CGT GTC ATA
TaqMan probe 5=-FAM-CAG AGA GAA GCC
CR2
TaqMan sense 5=-TGA GAC AAG CCA CAA
Taqman antisense 5=-GAA CGA GAT GTG GAC
TaqMan probe 5=-FAM-AAA GTG GAT TGA
CR5
TaqMan sense 5=-TGA GAC ATC CGT TCC
Taqman antisense 5=-TGA TGT CAT AGA TTG
TaqMan probe 5=-FAM-ACT CTC CCC GGG
XCR3
TaqMan sense 5=-GCC ATG GTC CTT GAG
Taqman antisense 5=-GGT CGA AGT TCA GGC
TaqMan probe 5=-FAM-CGA GGT TGC CGC
6PD
TaqMan sense 5=-TGC CCC CGA CCG TCT
Taqman antisense 5=-ATG CGG TTC CAG CCT
TaqMan probe 5=-FAM-ACT CGT GAA TGT
able 3. Gene Expression and Acute GVHD
Variable
umber of cases in which levels were increasing because of acut
GVHD
edian magnitude of increase (range)
umber of cases with an increased gene expression in connectio
diagnosis of GVHD
umber of cases with an increased gene expression before diagn
GVHD
edian number of days before diagnosis (range)
B&MTCR5
Increased mRNA levels of CCR5 in association
ith acute GVHD were detected in 35 of 46 occa-
ions. The median increase for these cases was 7
range, 2-156). The gene-expression levels increased
n close connection with acute GVHD in 18 cases and
median of 3 days (range, 1-16 days) before the
iagnosis in 17 cases. In 2 of 46 cases, the gene-
xpression levels were on a high level at the time of
cute GVHD, but no blood samples were available
efore this occasion. Therefore, the magnitude of
ncreases could not be calculated. The gene-expres-
ion levels were unchanged in connection with acute
VHD in 6 cases and were decreased in 3.
XCR3
Increases in gene-expression levels for CXCR3
ere seen in 33 of 46 cases in correlation with acute
VHD. The median increase was 12 (range,
-536). The increase was in close connection with
he diagnosis in 18 cases, and in 15 cases the increase
ence
Product Size
(Base Pairs)
A-3= 79
TC TGT-3=
ATG GAA AC-TAMRA-3=
AA-3= 90
ATG T-3=
GG ACG CAT TTC CC-TAMRA-3=
CA A-3= 83
TG ACA-3=
AC AAG ATG G-TAMRA-3=
GT-3= 160
GT C-3=
CT GG-TAMRA-3=
76
G-3=
GG TGA CGG CC-TAMRA-3=
CCR5 CXCR3 CCR1 CCR2
35 33 35 35
7 (2-156) 12 (2-536) 3 (2-26) 3 (2-322)
18 18 13 16
17 15 22 19Sequ
TTG G
GTC C
GGG
GCT G
AGC
ACA A
CCT A
GAC T
TGG A
GTG A
TGA A
CCT C
AC-3=
ATC Te
n with
osis of3 (1-16) 4 (1-8) 5 (1-14) 3 (1-12)
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2as seen a median of 4 days (range, 1-8 days) before
iagnosis of GVHD. For this marker, the levels were
lready on a high level in 2 of 46 cases, but no samples
ere available before GVHD. For CXCR3, 8 occa-
ions showed unchanged levels, and in 3 occasions the
ene-expression levels declined.
CR1
Thirty-ﬁve of the 46 episodes of acute GVHD
howed increasing levels of CCR1, with a median
ncrease of 3 (range, 2-26). Among these episodes,
3 cases showed increasing levels in close connection
ith acute GVHD, and in 22 cases there was an
pregulation of CCR1 5 days (range, 1-14 days) be-
ore acute GVHD was diagnosed clinically. In 4 of 46
ases of acute GVHD, the mRNA levels of CCR1
ere already on a high level when GVHD was diag-
osed, because of an earlier infection (n  2) and
ncomplete blood sampling (n  2). Therefore, in
hese 4 cases, the magnitude of increase could not be
alculated. Gene-expression levels were unchanged in
onnection with acute GVHD in 5 cases and declined
n 2 of 46 cases in connection with acute GVHD
iagnosis.
CR2
CCR2 showed increased expression levels in 35 of
6 episodes of acute GVHD. The median increase was
 (range, 2-322). In 16 of these cases, the increase
as seen in connection to the clinical diagnosis,
hereas in 19 cases the increase came 3 days (range,
-12 days) before the immunologic reaction was diag-
osed clinically. In 2 of the 46 diagnoses of acute
VHD, the gene-expression levels were on a high
evel before diagnosis, and the increase could there-
ore not be calculated. In 6 cases the levels were
nchanged, and declining levels were seen in 3 cases.
ll 4 Markers
When all 4 markers were evaluated at the same
ime, increased gene-expression levels of at least 1 of
he 4 markers were seen in 44 of 46 episodes of acute
VHD before or at the time of diagnosis. However,
n the vast majority of cases, the increased levels were
een in more than 1 marker. In 27 of the 44 cases, the
hemokine receptor expression decreased after
VHD treatment. The declining levels correlated
ell with response. In 8 cases, the gene expression was
ither increased or unchanged after therapy. In the
emaining 9 cases, the results could not be evaluated:
n most cases, this was due to a lack of blood samples
uring treatment. Furthermore, no signiﬁcant corre-
ation was found between the severity of GVHD and
he increase in transcript levels. No correlation be-
ween acute GVHD target organs and chemokine
eceptors was seen in these patients. t
84MV and Chemokine Receptor Gene Expression
CMV infection was diagnosed on 33 occasions in
1 patients. Both CCR5 and CXCR3 increased in 23
f 33 cases with CMV infection. The median increase
as 4.5 (range, 2-50) and 6.5 (range, 2-160)
or CCR5 and CXCR3, respectively. However, in 8
atients with increased gene expression of CCR5 and
XCR3, CMV infection and acute GVHD occurred
ithin 10 days. Moreover, the mRNA levels were
nchanged in 5 cases and were decreased in another 5.
he transcript levels of CCR1 were increased in 19 of
3 cases of CMV infection. The median increase was
 (range, 2-6). In 5 of these, CMV infection and
cute GVHD both occurred within 10 days. In 8
atients with CMV infection, the gene-expression lev-
ls of CCR1 declined. The remaining 6 patients
howed unchanged CCR1 levels in association with
MV infection. The fourth marker, CCR2, showed
ncreasing mRNA levels in 20 of 33 cases of CMV
nfection, with a median increase of 3 (range,
-12). Seven of these were in close connection with
iagnosis of acute GVHD. Decreasing levels of the
CR2 transcript were seen in 6 patients, and levels
ere unchanged in 7. We found decreasing levels of
ene expression in 10 cases during CMV therapy and
aw unchanged or increasing levels in 2 cases. In the
emaining 21 cases, the gene-expression levels could
ot be evaluated during therapy because of an insuf-
cient number of blood samples during that time
eriod.
ther Complications and Chemokine Receptor
ene Expression
Increases in gene-expression levels were not seen
xclusively in connection with acute GVHD. In 16,
6, 13, and 11 cases, the upregulation of mRNA ex-
ression for CCR5, CXCR3, CCR1, and CCR2, re-
pectively, was due to bacterial, viral, or fungal infec-
ions. Furthermore, in 9 cases, the gene-expression
evels of all 4 markers increased because of unknown
easons. In 6 of these patients, all with a mild skin rash
r slightly increased liver enzymes, the cyclosporine
oncentration in plasma was very low. All patients
ere treated with an increased cyclosporine dosage,
nd this resolved both the skin rash and the abnormal
iver enzymes. Therefore, it is possible that all these
atients had subclinical GVHD.
ISCUSSION
GVHD remains a major barrier to the wider ap-
lication of allogeneic SCT for a variety of diseases.
ecent advances in cytokine biology have led to an
mproved understanding of the pathophysiology of
his complex process. Because chemokines (chemotac-
ic cytokines) serve as critical mediators of leukocyte
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Chemokine Receptors and Acute GVHD
Becruitment and activation, various members of the
hemokine system may play a critical role in the mi-
ration of activated cells to target organs. Chemokine
xpression during allograft rejection has been demon-
trated in many experimental and clinical transplanta-
ion studies [12-15]. Moreover, studies using murine
odels of acute GVHD have demonstrated the criti-
al role of several chemokines and their receptors—
articularly MIP-1, MIP-2, Mig, monocyte che-
oattractant protein 1 and 3, and CCR5—in directing
-cell inﬁltration into target tissues during acute
VHD [11,16,33]. The goal of this study was to
dentify a reliable molecular marker of acute GVHD.
ecause chemokines seem to play an important role in
he process of acute GVHD, we investigated the cor-
elation between gene expression of the chemokine
eceptors CCR5, CXCR3, CCR1, and CCR2 in pe-
ipheral blood and GVHD in patients after allogeneic
CT.
In this study, we show that there is a correlation
etween the expression levels of CCR5, CXCR3,
CR1, and CCR2 and acute GVHD after allogeneic
CT. In 44 of the 46 cases of acute GVHD, the
ene-expression levels were upregulated in connection
ith diagnosis in at least 1 of the 4 markers. The
edian increases in connection with acute GVHD
iffered from 3 times for CCR1 and CCR2 to 12
imes for CXCR3. It is interesting to note that in
any patients, the mRNA levels increased some days
efore acute GVHD was diagnosed in the clinic. The
umber of days before ranged from 1 to 14, with a
edian time of 5 days for CCR1. Because it is well
nown that predicting the risk of acute GVHD before
ts clinical manifestation and administering additional
herapy early may result in less severe GVHD, this
nding may be important for early detection of an
volving GVHD reaction. In addition, these results
ere obtained even though gene-expression levels
ere not monitored daily. Hence, with a more fre-
uent collection of blood samples, early detection of
cute GVHD may have been even more pronounced.
The gene-expression levels of CCR5, CXCR3,
nd CCR2 were declining in 3 cases in association
ith acute GVHD diagnosis and were declining in
nly 2 cases for CCR1. The remaining cases were
ither increased because of earlier events or un-
hanged before acute GVHD. One patient, who de-
eloped acute GVHD grade IV, with unchanged lev-
ls in all 4 markers, was receiving a high dose of
teroids (because of metastases in the brain) for more
han a month before acute GVHD diagnosis. The
naffected gene-expression levels may have been due
o the steroid treatment.
No signiﬁcant correlation was found between the
everity of GVHD and the increase in transcript levels
f the chemokine receptors. It has been shown previ-
usly that CCR5-expressing T lymphocytes are re- p
B&MTruited to the liver during acute GVHD in mouse
odels [16] and that MIP-1, a ligand for CCR1 and
CR5, also seems to be involved in liver GVHD [33].
ecently, Duffner et al. [34] showed that the migra-
ion of donor CD8	 T cells to GVHD target organs
uch as the intestines depends on the expression of
XCR3 and that the expression of this receptor sig-
iﬁcantly contributed to GVHD damage and overall
ortality in mice. However, we could not conﬁrm a
orrelation between the chemokine receptors and the
ffected target organs in this study. In vitro studies,
owever, have documented a redundancy of chemo-
ines and receptors. Few receptors bind a single li-
and, and several chemokines can bind to more than 1
eceptor. Therefore, ﬁnding a correlation between
xpression of chemokine receptors and target organ
njury in this limited patient material may be difﬁcult.
n addition, patient studies are more complex and are
nﬂuenced by more parameters than controlled studies
erformed on GVHD models in mice.
The results in this study indicate that the increase
n chemokine receptor expression is not unique to the
cute GVHD. Hence, we found increasing levels in
onnection with CMV infection. Increasing levels
ere seen in 23 of 33 cases for CCR5 and CXCR3.
pregulation of CCR1 and CCR2 gene expression
as seen in 19 and 20 cases, respectively. It is note-
orthy that in 3 cases, acute GVHD and CMV infec-
ion were diagnosed on the same day. Therefore, the
ncreases can be due to CMV, acute GVHD, or both.
he actual reason for the increase is hard to elucidate.
Furthermore, high expression levels of the 4 mark-
rs were seen not only during acute GVHD and CMV
nfections, but also during other immunologic events,
uch as bacterial, fungal, and other viral infections.
owever, these infections may be detected and diag-
osed by other existing diagnostic methods. In 9 pa-
ients, the reason for the high expression levels of
CR5, CXCR3, CCR1, and CCR2 remain unclear.
owever, 6 of these patients showed a mild skin rash
r slightly increased liver enzymes levels during this
ime. The skin rash and the abnormal liver enzymes
evels resolved in all 6 patients when the cyclosporine
oncentration was doubled. Therefore, a subclinical
cute GVHD may have been the explanation for the
ncreases seen in 6 of these 9 patients. These patients
how the occasional difﬁculties in diagnosing acute
VHD. Therefore, it is possible that all 6 patients had
cute GVHD or at least subclinical GVHD at the
ime of increased chemokine receptor levels.
Although the role of various chemokines in regu-
ating donor T-cell migration to GVHD target tissues
emains unexplained, in this study we conﬁrmed pre-
ious ﬁndings showing the importance of some of the
eceptors in the pathophysiology of acute GVHD
16]. To our knowledge, this has not been shown in
atients before. Chemokines and chemokine receptors
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2ave been proposed to be the novel target molecules
f therapeutic interventions for acute GVHD
11,16,33]. In this study, we showed that chemokine
eceptors such as CCR5, CXCR3, CCR1, and CCR2
eem to be important in the context of acute
VHD—not only as therapeutic targets, but also as
olecular markers for acute GVHD detection. How-
ver, additional follow-up studies with more patients
nd more frequent monitoring are required to conﬁrm
he ﬁndings observed in this study. Although not spe-
iﬁc for acute GVHD, our study indicates that che-
okine receptors, especially CCR5, CXCR3, CCR1,
nd CCR2, can be used to monitor and diagnose acute
VHD after allogeneic SCT.
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